TXNDC5 and plasma cell myeloma: Analogously, the high expression of TXNDC5 in plasma cells of bortezomib-resistant refractory/relapsed multiple myeloma (RRMM) patients suggests that TXNDC5 may be a bortezomib resistance marker or a potential RRMM treatment target [64].